EUCTR2011-006132-24-HU
进行中（未招募）
不适用
A multi-centre 3-year follow-up study to assess the viral activity in patients who failed to achieve sustained virologic response in Novartis-sponsored alisporivir studies for chronic hepatitis C patients
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- ovartis Pharma Services AG
- 入组人数
- 650
- 状态
- 进行中（未招募）
- 最后更新
- 12年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •\-Written informed consent must be obtained before any assessment is performed
- •\-Males or females aged 18 or greater
- •\-Have previously completed a Novartis\-sponsored hepatitis C study and received alisporivir or a direct antiviral agent
- •\-Have not acheived SVR24
- •\-Be able to comply with visit schedule
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 650
- •F.1\.3 Elderly (\>\=65 years) yes
排除标准
- •\-Use of any investigational drugs within 5 half\-lives of enrollment, or within 30 days of that medication, whichever is longer
- •\-Previous use of any course of hepatitis C therapy since the end of the Novartis\-sponsored hepatitis C study
结局指标
主要结局
未指定
相似试验
进行中（未招募）
1 期
A 3-year follow-up study in chronic hepatitis C patients who failed to achieve sustained virologic response during Novartis-sponsored alisporivir studiesChronic hepatitis C patients who failed to achieve sustained virologic response (SVR24) on alisporivir or direct-acting antivirals (DAA) in previous Novartis-sponsored studies.MedDRA version: 14.1Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2011-006132-24-GBovartis Pharma Services AG105
进行中（未招募）
不适用
A 3-year follow-up study of chronic hepatitis C patients treated with alisporivir to assess durability of sustained virologic responseEUCTR2011-006131-38-GBovartis Pharma Services AG2,000
进行中（未招募）
3 期
A study to assess thedurability of sustained virologic response in Alisporivirtreatedchronic Hepatitis C patientsHealth Condition 1: null- chronic Hepatitis CCTRI/2012/10/003066ovartis Healthcare Pvt Lt2,000
进行中（未招募）
不适用
A 3-year follow-up study in chronic hepatitis C patients who failed to achieve sustained virologic response during Novartis-sponsored alisporivir studiesChronic hepatitis C patients who failed to achieve sustained virologic response (SVR24) on alisporivir or direct-acting antivirals (DAA) in previous Novartis-sponsored studies.MedDRA version: 14.1Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2011-006132-24-ESovartis Farmaceutica, S.A.650
进行中（未招募）
不适用
A 3-year follow-up study of chronic hepatitis C patients treated with alisporivir to assess durability of sustained virologic responseEUCTR2011-006131-38-ITOVARTIS FARMA2,000